Skip to main content
SpringerLink
Log in

Clinical relevance

  • Chapter
Clinical Nephrotoxins

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nolan CR, Anderson RJ. Hospital-acquired acute renal failure. JASN 1998; 9: 710–718.

    CAS  PubMed  Google Scholar 

  2. Vijayan A, Miller SB. Acute renal failure: prevention and non-dialytic therapy. Sem. Nephrol 1998; 18: 523–532.

    CAS  Google Scholar 

  3. Turney JH, Marshall DH, Brownjohn AM, Ellis CM and Parsons FM. The evolution of acute renal failure 1956–1988. Q J Med 1990; 73: 83–104.

    Google Scholar 

  4. Rasmussen HH, Ibels LS. Acute renal failure: multi variant analysis of causes and risk factors. Am J Med 1982; 73: 211–218.

    Article  CAS  PubMed  Google Scholar 

  5. Hou SH, Bushunsky DA, Wish BB, Cohen JJ, Harrington IT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74: 243–248.

    Article  CAS  PubMed  Google Scholar 

  6. Kleinknecht D, Landais P, Goldfarb B. Les insuffisances renales aigues associees 11 des medicaments OU 11 des produits de contraste iodes. Resultats ďune enquete cooperative multicentrique de la société de Néphrologie. Néphrologie 1986; 7: 41–46.

    CAS  PubMed  Google Scholar 

  7. Kaufman J, Dhakal M, Patel B, Hamburger R. Community-acquired acute renal failure. Am J Kidney Dis 1991; 17: 191–198.

    CAS  PubMed  Google Scholar 

  8. Bennett WM, Porter GA. Overview of clinical nephrotoxicity. In: Toxicology of the kidney. Hook IB, Goldstein RS (editors). Raven Press, New York 1993; p. 61–97.

    Google Scholar 

  9. Baraldi A, Ballestri M, Rapana R, Lucchi L, Borella P, Leonelli M, Furci L and Lusvarghi E. Acute renal failure of medical type in an elderly population. Nephol Dial Transpl 1998; 13(supp7): 25–29.

    Google Scholar 

  10. Khan IH, Catto GRD, Edward N, Macleod AM. Acute renal failure: factors influencing nephrology referral and outcome. Q J Med 1997; 90: 781–785.

    CAS  Google Scholar 

  11. Feest TG, Round A, Hamad S. Incidence of severe acute renal failure in adults: results of a community based study. Br Med J 1993; 306: 481–483.

    CAS  Google Scholar 

  12. Pruchnicki MD, Dasta JF. Acute renal failure in hospitalized patients: part I. Ann Pharmacother 2002; 36: 1261–1267.

    PubMed  Google Scholar 

  13. Margrra S, Kraft AK, Siebert G, Luft FC, Neumayer HH. Long-term outcomes in acute renal failure patients treated with continuous replacement therapies. Am J Kidney Dis 2002; 40: 275–279.

    Google Scholar 

  14. Davidman M, Olsen P, Kohen J, Leither T, Kjellstrand C. Iatrogenic renal disease. Arch Intern Med 1991; 151: 1809–1812.

    Article  CAS  PubMed  Google Scholar 

  15. Pru C, Ebben J, Kjellstrand C. Chronic renal failure after acute tubular necrosis. Kidney Int 1982; 21: 176.

    Google Scholar 

  16. Fleury D, Vanhille P, Pallot IL, Kleinknecht D. Drug induced acute renal failure: a preventable disease linked to drug misuse. Kidney Int 1990; 38: 1238.

    Google Scholar 

  17. Wing AJ, Broyer M, Brunner FP, Brynger H, Challah S, Challah S, Donckerwolcke RA, Gretz N, Jacobs C, Kramer P, Selwood NH. Combined report on regular dialysis and transplantation in Europe XIII Acute (reversible) renal failure. Proc Eur Dial Transpl Assoc 1983; 20: 64–71.

    Google Scholar 

  18. Ronco C, Zanella M, Brendolan A, Milan M, Canato G, Zamperetti N, Bellomo R. Management of severe acute renal failure in critically ill patients: an international survey in 345 centres. Nephrol Dial Transplant 2001; 16(2): 230–237.

    CAS  PubMed  Google Scholar 

  19. Frankel MC, Weinstein AM, Stenzel KH. Prognostic patterns in acute renal failure: the New York Hospital, 1981–1982. Clin Exp Dialysis Apheresis 1983; 7: 1457.

    Google Scholar 

  20. Beard K, Perera DR, Lick H. Drug induced parenchymal renal disease in outpatients. J Clin Pharmacol 1988; 28: 431–435.

    CAS  PubMed  Google Scholar 

  21. Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, Rosen S: Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int 1991; 40: 632–642.

    CAS  PubMed  Google Scholar 

  22. Dishart M, Kellum JA. An evaluation of pharmacological strategies fro the prevention and treatment of acute renal failure. Drugs 2000; 59: 79–91.

    Article  CAS  PubMed  Google Scholar 

  23. Dekant W, Vamvakas S. Biotransformation and membrane transport in nephrotoxicity. Crit Rev Toxicol 1996; 26: 309–334.

    CAS  PubMed  Google Scholar 

  24. Tune B. The nephrotoxicity of cephalosporin antibiotics. Sturcture-activity relationship. Commun Toxicol 1993; 1: 145–157.

    Google Scholar 

  25. Pearson PG, Omichinski JG, Holme JA, McClanahan RH, Brunborg G, Soderlund EJ, Dybing E, Nelson SD: Metabolic activation of tris (2, 3, dibromopropyl) phosphate to reactive intermediates: Covalent binding, reactive metabolite formation and differental metabolite-specific DNA damage, in vivo. Toxicol Appl Pharmacol 1993; 118: 186–196.

    CAS  PubMed  Google Scholar 

  26. Goyer RA. Mechanisms of lead and cadmium nephrotoxicity. Toxicol Lett 1989; 46: 153–176.

    Article  CAS  PubMed  Google Scholar 

  27. Kaloyanides GJ. Aminoglycoside-induced functional and biochemical defects in the renal cortex. Fundam Appl Toxicol 1984; 4: 930–942.

    Article  CAS  PubMed  Google Scholar 

  28. Albano E, Rundgren M, Harvison PJ, Nelson SD, Moldeus P. Mechanisms of N-acetyl-p-benzoquinone imine cytotoxicity. Mol Pharmacol 1985; 28: 306–315.

    CAS  PubMed  Google Scholar 

  29. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiological foundations and clinical implications. Am J Med 1999; 106: 13S–24S.

    Article  CAS  PubMed  Google Scholar 

  30. Kleinknecht D. Diseases of the kidney caused by nonsteroidal anti-inflammatory drugs. In. Stewart JH (editor). Oxford University Press, Oxford 1993; p. 160–173.

    Google Scholar 

  31. Bridoux F, Hazzan M, Pallot JL, Fleury D, Lemaitre V, Kleinknecht D, Vanhille Ph. Acute renal failure after the use of angiotensin-converting enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial Transplant 1992; 7: 100–104.

    CAS  PubMed  Google Scholar 

  32. Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A. The outcome of acute interstitial nephritis: Risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2000; 54: 179–190.

    CAS  PubMed  Google Scholar 

  33. Kleinknecht D, Landais P, Goldfarb B. Pathophysiology and clinical aspects of drug-induced tubular necrosis in man. Contr Nephrol 1987; 55: 145–158.

    CAS  Google Scholar 

  34. Richet G, Sraer JD, Kourilsky O. La ponction-biopsic rénale dans l’insuffisance rénale aigue. Ann Med Interne 1978; 129: 335–337.

    Google Scholar 

  35. Linton AL, Clark W, Driedger AA, Turnbull DJ, Lindsey RM. Acute interstitial nephritis due to drug. Review of the literature with a report of nine cases. Ann Intern Med 1980; 93: 735–741.

    CAS  PubMed  Google Scholar 

  36. Buysen JGM, Houthoff HJ, Kredict RT, Arisz L. Acute interstitial nephritis, a clinial and morphological study in 27 patients. Nephrol Dial Transpl 1990; 5: 94–99.

    CAS  Google Scholar 

  37. Grunfeld JP, Kleinknecht D, Droz D. Acute interstitial nephritis. In: Diseases of the kidney. Schrier RW, Gottschalk CW (editors). Little Brown, Boston 1993; p. 1331–1353.

    Google Scholar 

  38. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001; 60: 804–817.

    Article  CAS  PubMed  Google Scholar 

  39. Choudhury D, Ahmed Z. Drug-induced nephrotoxicity. Med Clin N Am 1997; 81: 705–717.

    Article  CAS  PubMed  Google Scholar 

  40. Richards JR, Johnson EB, Stark RW, Derlet RW. Methamphetamine abuse and rhabdomyolysis in the ED: A 5-year study. Am J Emerg Med 1999; 17: 681–685.

    Article  CAS  PubMed  Google Scholar 

  41. Lieberthal W, Levinsky NG. Acute renal failure. In: The kidney: physiology and pathophysiology. Seldin W, Giebish G (editors). Raven Press, New York 1992; p. 3181–3225.

    Google Scholar 

  42. Wolfe JA, McCann RL, Sanfillipo F. Cyclosporine-assoicated microangiopathy in renal transplantation: a severe but potentially — reversible form of early graft injury. Transplantation 1986; 41: 541.

    Google Scholar 

  43. Personal communication, Evans, T, McNeil Consumer Health Care, 2000.

    Google Scholar 

  44. Henrich WL. Nephrotoxicity of non-steroidal anti-inflammatory agents. In: Diseases of the kidney. Schrier RW, Gottschalk CW (editors). Little Brown, Boston 1993; p. 1203–1217.

    Google Scholar 

  45. Nicholls AJ, Shortland JR. Brown CB. Mefenamic acid nephropathy — A spectrum of renal lesions. Proc Eur Dial Transpl Assoc 1985; 22: 991–996.

    Google Scholar 

  46. Corwin HL, Bonventre JV. Renal insufficiency associated with non-steroidal anti-inflammatory agents. Am J Kidney Dis 1984; 4: 147–152.

    CAS  PubMed  Google Scholar 

  47. Kleinknecht D, Landais P, Goldfarb B. Analgesic and nonsteroidal anti-inflammatory drug-associated acute renal failure. A prospective study. Clin Nephrol 1986; 25: 275–281.

    CAS  PubMed  Google Scholar 

  48. Makdassi R, Andrejak M, Westeel PF, Schmit JL, Renaud H, Houhou S, Fournier A. Aetiology and prognosis of iatrogenic renal failure on the basis of a 6-year experience. Nephrol Dial Transplant 1990; 5: 660–661.

    Google Scholar 

  49. Boiskin M, Marcussen N, Kjellstrand C. ACE inhibitors are now the second most common cause of acute, iatrogenic renal failure. J Am Soc Nephrol 1992; 3: 720.

    Google Scholar 

  50. Schusterman N, Strom BL, Murray TG, Morrison G, West SL, Maislin G. Risk factors and outcome of hospital-acquired acute renal failure. Am J Med 1987; 83: 65–71.

    Google Scholar 

  51. Rudnick M, Berns JS, Cohen RM, Goldfarb 5. Contrast media-assoicated nephrotoxicity. Curr Opin Nephrol Hyperten 1996; 5: 127–133.

    CAS  Google Scholar 

  52. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kid Internat 1994; 45: 259–265.

    CAS  Google Scholar 

  53. Levey AS. Measurement of renal function in chronic renal disease. Kidney Int 1990; 38: 167–184.

    CAS  PubMed  Google Scholar 

  54. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations ofcreatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830–838.

    CAS  PubMed  Google Scholar 

  55. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 312–318.

    CAS  PubMed  Google Scholar 

  56. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, Vera M, Piera C, Darnell A: Serum cystatin C as a new marker for noninvasive estimation ofglomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29–34.

    CAS  PubMed  Google Scholar 

  57. Aviv A, John E, Bernstein J, Goldsmith DI, Spitzer A. Lead intoxication during development. Its late effects on renal function and blood pressure. Kidney Int 1980; 17: 430–443.

    CAS  PubMed  Google Scholar 

  58. Parker RA, Bennett WM, Porter GA. Animal models in the study of aminoglycoside nephrotoxicity. In: The aminoglycosides: microbiology, clinical use and toxicology. Whelton A, Neu HC (editors). Marcel Dekker Inc, New York, Basel, 1982; 235–268.

    Google Scholar 

  59. Nicolau DP, Freeman CD, Belliveau PP. Experience with once-daily aminoglycoside program administrated to 2184 adult patients. Antimicrob. Agent Chemother 1995; 39: 650–655.

    CAS  Google Scholar 

  60. Swan RC, Merrill JP. The clinical course of acute renal failure. Medicine 1953; 32: 215–292.

    Google Scholar 

  61. US Renal Data System, USRDS 2000 Annual Data Report: Atlas of end-stage renal disease in the United States. National Institutes of Health, Nathional Institute of Diabetes and Digestive and Kidney Diseases, Bethesda MD, 2000.

    Google Scholar 

  62. Combined report on regular dialysis and transplantation in Europe, XIX, 1988. Nephrol Dial Transplant 1989; 4(Suppl4): 5–29.

    Google Scholar 

  63. Porter GA. Bennett WM, Gilbert DN. Unraveling aminoglycoside nephrotoxicity using animal models. J Clin Pharmacol 1983; 23: 445–452.

    CAS  PubMed  Google Scholar 

  64. Steenland NK, Thun MJ, Ferguson CW, Port FK Occupational and other exposures associated with male end-stage renal disease: a case/control study. Am J Pub Health 1990; 80: 153–159.

    CAS  PubMed  Google Scholar 

  65. O’Dea DF, Murphy SW, Hefferton D, Parfrey PS. Higher risk for renal failure in first-degree relatives of white patients with end-stage renal disease: A population based study. Am J Kidney Dis 1998; 32: 794–801.

    CAS  PubMed  Google Scholar 

  66. Freedman BI, Soucie M, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kid Dis 1999; 34: 254–258.

    CAS  PubMed  Google Scholar 

  67. Wang Y, Kikuchi S, Suzuki H, Nagase S, Koyama A. Endothelial nitric oxide synthase gene polymorphism in intron 4 affects the progression of renal failure in non-diabetic renal disease. Nephrol Dial Transplant 1999; 14(12): 2898–2902.

    CAS  PubMed  Google Scholar 

  68. Gumprecht J, Zychma J, Grzeszczak W, Zukowska-Szczechowska E, and ESRD study group. Angiotension I converting enzyme gene insertion/deletion and angiotensiongen M235T polymorphism. Kidney Int 2000; 58: 513–519.

    Article  CAS  PubMed  Google Scholar 

  69. Nobilis A, Kocsis I, Toth-Heyn P, Treszl A, Schuler A, Tulassay T, Vasarhelyi B. Variance of ACE and AT1 receptor gene does not influence the risk of neonatal acute renal failure. Pediatr Nephrol 2001; 16(12): 1063–1066.

    Article  CAS  PubMed  Google Scholar 

  70. Sandler DP, Smith JC. Chronic renal disease risk associated with employment in industries with potential solvent exposure. In: Nephrotoxicity mechanisms: early diagnosis and therapeutic management. Bach PH, Gregg NJ, Wiks MF, Delacruz L (editors). Marcel Dekker Inc, New York 1991: p 261–266.

    Google Scholar 

  71. Landrigan PJ, Goyer RA, Clarkson TW, Sandler DP, Smith JH, Thun MJ, Wedeen RP. The work-relatedness of renal disease. Arch Environ Health 1984; 39: 225–230.

    CAS  PubMed  Google Scholar 

  72. Bennett WM, EIzinga LW, Porter GA. Tubulointerstitial diseasc and toxic nephropathy. In: The kidney. Brenner BM, Rector FC Jr (editors). WB Saunders, Philadelphia 1991; p 1430–1496.

    Google Scholar 

  73. Gregg NJ, Elseviers MM, De Broe ME, Bach PH. Epidemiology and mechanistic basis of analgesic nephropathy Toxicol Lett 1989; 46: 141–151.

    Article  CAS  PubMed  Google Scholar 

  74. Sandler DP. Epidemiology in the assessment of nephrotoxicity. In: Nephrotoxicily in the experimental and clinical situation. Bach PH, Locke EA (editors). Martinus Nijhoff, Dordrecht 1987; 847–883.

    Google Scholar 

  75. Staessen J, Yeoman WB, Fletcher AE, Markowe HLJ, Marmot MG, Rose G, Semmence A, Shipley MJ, Bulpitt CJ. Blood lead concentration, renal function and blood pressure in London civil servants. Brit J Ind Med 1990; 47: 441–447.

    Google Scholar 

  76. Iesato K, Wakastin M, Wakastin Y. Renal tubular dysfunction in Minimata disease. Ann Intern Med 1977; 86: 731–733.

    CAS  PubMed  Google Scholar 

  77. Staessen JA, Lauwerys RR, Buchet JP, Bulpitt CJ, Rondia D, Vanrenterghem Y, Amery A, Cadmibel Study Group. Impairment of renal function with increasing blood lead concentrations in the general population. N Engl J Med 1992; 327. 151–156.

    CAS  PubMed  Google Scholar 

  78. Vanherweghem JL. Misuse of herbel rememdies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J Altern Complement Med 1998; 4: 9–13.

    CAS  PubMed  Google Scholar 

  79. De Broe ME. On a nephrotoxic and carcinogenic slimming regime. Am J Kidney Dis 1999; 33: 1171–1173.

    PubMed  Google Scholar 

  80. Lord G, Tagore R, Cook T, Gower P, Pusey CD. Nephropathy caused by Chinese herbs in the UK. Lancet 1999; 354: 481–482.

    Article  CAS  PubMed  Google Scholar 

  81. Moore RD, Smith CR, Lipsky JJ, Mellitus ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100: 352–373.

    CAS  PubMed  Google Scholar 

  82. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int 1999; 55: 278–285.

    Article  CAS  PubMed  Google Scholar 

  83. Anderson S, Rennke H, Brenner B. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993–2000.

    CAS  PubMed  Google Scholar 

  84. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM. The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis 1993; 21: 387–393.

    CAS  PubMed  Google Scholar 

  85. Obialo CI, Crowell AK, Okonofua EC. Acute renal failure mortality in hospitalized African Americans: age and gender considerations. J Natl Med Assoc 2002; 94(3): 127–134.

    PubMed  Google Scholar 

  86. Porter GA. Risk factors for toxic nephropathies. Toxicol Lett 1989; 46: 269–279.

    Article  CAS  PubMed  Google Scholar 

  87. Cremer W, Bock KD. Symptoms and causes of chronic hypokalemic nephropathy in man. Clin Nephrol 1977; 7: 112–123.

    CAS  PubMed  Google Scholar 

  88. Wedeen RP. Poison in the pot. The legacy of lead. So Illinois Univ Press, Carbondale 1984.

    Google Scholar 

  89. Mudge GH. Analgesic nephropathy: renal drug distribution and metabolism. In: Nephrotoxic mechanisms of drugs and environmental toxins. Porter GA (editor). Plenum Med Book Co, New York, London 1982; p 209–225.

    Google Scholar 

  90. Itizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int 1999; 55: 1945–1951.

    Google Scholar 

  91. Stenvinkel P, Heimburger O, Paultre F, Diczfulusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899–1911.

    Article  CAS  PubMed  Google Scholar 

  92. Morgan JM, Hartley MW. Etiologic factors in lead nephropathy. South Med J 1976; 69: 1445–1449.

    CAS  PubMed  Google Scholar 

  93. Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD. Acute renal failure following binge drinking and nonsteroidal anti-inflammatory drugs. Am J Kidney Dis 1992; 20: 281–285.

    CAS  PubMed  Google Scholar 

  94. Perneger TV, Whelton PK, Puddey IB, Klag MJ. Risk of end-stage renal disease associated with alcohol consumption. Am J Epidemol 1999; 150: 1275–1281.

    CAS  Google Scholar 

  95. Emmerson BT. Chronic lead nephropathy. Kidney Int 1973; 4: 1–5.

    CAS  PubMed  Google Scholar 

  96. Rodriguez-Puyol D. The aging kidney. Kidney Int 1998; 54: 2247–2265

    CAS  PubMed  Google Scholar 

  97. Bennett WM. Geriatric pharmacokinetics and the kidney. Am J Kidney Dis 1990; 16: 283–288.

    CAS  PubMed  Google Scholar 

  98. Kohli HS, Bhaskaran MC, Muthukumar T, Thennarasu K, Sud K, Jha V, Gupta KL, Sakhuja V. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transpl 2000; 15: 212–217.

    Article  CAS  Google Scholar 

  99. Chester AC, Rakowski TI. Argy WP, Giacalone A, Schreiner GE. Hemodialysis in the eighth and ninth decade of lite. Arch Intern Med 1979; 139: 1001–5.

    Article  CAS  PubMed  Google Scholar 

  100. Marcias-Nunez IE, Cameron lS. Renal function and disease in the elderly. London, Boston, Durban, Singapore, Sydney, Toronto, Wellington: Butterworth 1987: p 503.

    Google Scholar 

  101. Mudge GH. Nephrotoxicity of urographic radiocontrast drugs. Kidney Int 1980; 18: 540–552.

    CAS  PubMed  Google Scholar 

  102. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. J Am Med Assoc 1996; 275: 1489–1494.

    CAS  Google Scholar 

  103. Evans JMM, McGregor E, McMahon AD, McGilchrist MM, Jones MC, White G, McDevitt DG, MacDonald TM: Non-steroidal drugs anti-inflammatory drugs and hospitalization for acute renal failure. Q J Med 1995; 88: 551–557.

    CAS  Google Scholar 

  104. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJM, the French Study Group on Acute Renal Failure. Acute renal failure in intensive care units: causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. Crit Care Med 1996; 24: 192–198.

    Article  CAS  PubMed  Google Scholar 

  105. Liano F, Junco E, Pascual J, Madero R, Verde E, and the Madrid Acute Renal Failure Study Group. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. Kidney Int 1998; 66: S16–S24.

    CAS  Google Scholar 

  106. Cole L, Bellomo R, Silvester W, Reeves JH. A prospective, multicenter study of the epidemiology, management, and outcome of severe acute renal failure in a “closed” ICU system. Am J Respir Crit Care Med 2000; 162: 191–196

    CAS  PubMed  Google Scholar 

  107. deMendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, Takala J, Sprung C, Cantraine FP. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000; 26: 915–921.

    PubMed  Google Scholar 

  108. De long PE, Statius van Eps LW. Sickle cell nephropathy: new insights into its pathophysiology. Kidney Int 1985; 27: 711–719.

    Google Scholar 

  109. Allen M, Lawson L, Eckman lR, Delaney V, Bourke E. Effects of nonsteroidal anti-inflammatory drugs on renal function in sickle cell anemia. Kidney Int 1988; 34: 500–506.

    Google Scholar 

  110. Porter GA. Contrast associated nephropathy. Am J Cardiol 1989; 64: 22E–26E.

    Article  CAS  PubMed  Google Scholar 

  111. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105(19): 2259–2264.

    Article  PubMed  Google Scholar 

  112. Rao TK, Nicastri AD, Friedman EA. Natural history of heroin-associated nephropathy. N Engl J Med 1974; 290: 19–25.

    CAS  PubMed  Google Scholar 

  113. Dubrow A, Mittman N, Ghali V, Flamenbaum W. The changing spectrum of heroin associated nephropathy. Am J Kidney Dis 1985; 5: 36–43.

    CAS  PubMed  Google Scholar 

  114. Cunningham EE, Zielezny MA, Venuto RC. Heroin-associated nephropathy — a nationwide problem. JAMA 1983; 250: 2935–2938.

    Article  CAS  PubMed  Google Scholar 

  115. Warner E. Cocaine abuse. Ann Intern Med 1993; 119: 226–235.

    CAS  PubMed  Google Scholar 

  116. Roth D, Alarcon FJ, Fernandez JA, Preston RA, Bougoignie JJ. Acute rhabdomyolysis associated with cocaine intoxication. N Engl J Med 1988; 319: 673–677.

    CAS  PubMed  Google Scholar 

  117. van der Woude FJ. Cocaine use and kidney damage. Nephrol Dial Transplant 2000; 15: 299–301.

    PubMed  Google Scholar 

  118. Citron BP, Halpern M, McCarron M. Lundberg GD, McCormick R, Pincus IJ, Tatter D, Haverback BJ. Necrotizing angitis associated with drug abuse. N Engl J Med 1970; 283: 1003–1007.

    CAS  PubMed  Google Scholar 

  119. Bingham C, Beaman M, Nicholls AJ, Anthony PP. Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3, 4-methylenedioxymethamphetamine (‘ecstacy’). Nephrol Dial Transplant 1998; 13: 2654–2655.

    CAS  PubMed  Google Scholar 

  120. Richards JR, Johnson EB, Stark RW, Derlet RW. Methamphetamine abuse and rhabdomyolysis in the ED: A 5 year study. Am J Emerg Med 1999; 17: 681–685.

    Article  CAS  PubMed  Google Scholar 

  121. Porter GA. Antimicrobial nephrotoxicity. In: Textbook of nephrology. Massry SG, Glassock JR (editors). Baltimore, Williams & Wilkins 1989; p 812–818.

    Google Scholar 

  122. Swartz RD, Rubin JE, Leeming BW, Silva P. Renal failure following major angiography. Am J Med 1978; 65: 31–37.

    Article  CAS  PubMed  Google Scholar 

  123. Cochran ST, Wong WS. Roe DJ. Predicting angiographic-induced acute renal impairment: clinical risk model. Am J Radiol 1983; 141: 1027–1033.

    CAS  Google Scholar 

  124. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86: 649–652.

    CAS  PubMed  Google Scholar 

  125. Leehey DJ, Braun DA. Tholl LS, Chung CA, Gross JA, Lentino JR. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy? J Am Soc Nephrol 1993; 4: 81–90.

    CAS  PubMed  Google Scholar 

  126. Swann SK, Bennett WM. Nephrotoxic acute renal failure. In: Acute renal failure. Lazarus JM, Brenner BM (editors). Churchill Livingston, New York, 1993; p 357–392.

    Google Scholar 

  127. Levenson DJ, Simmons CE, Brenner BM. Arachidonic acid metabolism, prostaglandins and the kidney. Am J Med 1982; 72: 354–374.

    Article  CAS  PubMed  Google Scholar 

  128. Whelton A. Renal and related cardiovascular effects of conventional and COX-2 specific NSAIDs and non-NSAID analgesics. Am J Ther 2000; 7: 63–74.

    CAS  PubMed  Google Scholar 

  129. Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002; 288(20): 2547–2553.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oregon Health Sciences University, Portland, Oregon, USA

    George A. Porter

  2. University of Texas Southwestern Medical Center, Dallas, Texas, USA

    Biff F. Palmer

  3. University of Maryland School of Medicine, Baltimore, Maryland, USA

    William L. Henrich

Authors
  1. George A. Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Biff F. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William L. Henrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nephrology and Hypertension, University of Antwerp, Belgium

    Marc E. de Broe

  2. Department of Medicine, The Oregon Health Sciences University, Portland, Oregon, USA

    George A. Porter

  3. Northwest Renal Clinic, Legacy Good Samaritan Hospital, Portland, Oregon, USA

    William M. Bennett

  4. Department of Nephrology and Hypertension, University of Antwerp, Belgium

    Gert A. Verpooten

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Kluwer Academic Publishers

About this chapter

Cite this chapter

Porter, G.A., Palmer, B.F., Henrich, W.L. (2003). Clinical relevance. In: de Broe, M.E., Porter, G.A., Bennett, W.M., Verpooten, G.A. (eds) Clinical Nephrotoxins. Springer, Dordrecht. https://doi.org/10.1007/1-4020-2586-6_1

Download citation

  • DOI: https://doi.org/10.1007/1-4020-2586-6_1

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-1277-8

  • Online ISBN: 978-1-4020-2586-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation